Biotech Values

[DewDiligence]

Re: Teva’s Lovenox

Thanks, pollyvonwog. As is probably clear from the prior posts in this thread, I believe that Teva is not playing with a full deck with respect to this matter. Let’s examine the statements by Teva’s IR department in more detail:

“It is well-known that we have partnered with another company regarding the product [Lovenox].”

I’ll bet that few if any sell-side analysts covering MNTA know this. If they did, they presumably would have mentioned it somewhere along the line when they opined as to the likelihood of Teva’s getting FDA approval.

“We are very pleased with our partner for generic Lovenox.”

Uh, huh. It’s been almost 7.5 years since Teva submitted its Lovenox ANDA. I can certainly see why they would be pleased with the outcome.

“I am not sure I understand why that would be consequential.”

This is IMO even more disingenuous than the statement above about being pleased. Unless the individual in Teva’s IR is completely out of the loop, he knows damn well why the identity of Teva’s partner is a consequential matter.